Cypher drug-Eluting stent: a Zwolle Acute myocardial infarction Randomised trial

INTERVENTION: Percutaneous Coronary Intervention using either the Bx VELOCITYTM stent coated with rapamycin (Cypher) or the TaxusTM stent coated with Paclitaxel. CONDITION: Acute myocardial infarction ; Circulatory System ; Infarction PRIMARY OUTCOME: Major adverse cardiac clinical events (death, re‐infarction, target vessel revascularisation) at one, nine and 12 months after treatment. SECONDARY OUTCOME: Late lumen loss at nine months follow‐up by quantitative coronary angiography INCLUSION CRITERIA: 1. Patients with acute myocardial infarction, presenting within six hours after symptom‐onset, or those presenting between six and 24 hours if persisting chest pain associated with clinical evidence of on‐going ischaemia occurs 2. Culprit lesion in a native coronary artery, suitable for stenting 3. Lesion length of less than 30 mm, located in a vessel of more than 2.5 mm 4. Able to deliver the stent to target lesion (absence of diffuse disease or excessive proximal vessel tortuosity) 5. Absence of no‐reflow or extensive thrombus throughout vessel